Targeted Therapy for Rare Blood Cancers
An inhibitor of the growth-stimulating FGFR1 protein was approved for patients with a rare type of blood cancer. The...
Progress Against Cancer
An inhibitor of the growth-stimulating FGFR1 protein was approved for patients with a rare type of blood cancer. The...
The FDA granted accelerated approval to the first HER2-targeted therapy for the treatment of non-small cell lung cancer with...
The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The...
The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food...
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S....
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S....
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. ...
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S....
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E...
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment...